A Study of BND-35 in Participants With Advanced Solid Tumors

Inclusion Criteria:

• Patients with unresectable or metastatic disease who are refractory to or are notcandidates for standard approved therapy

• Histologic confirmation of malignancy

• Measurable disease per RECIST v1.1

• Eastern Cooperative Oncology Group Performance Status (ECOG) of 0 or 1

• Participants must have adequate organ function as defined by laboratory tests

• Part 1: Following tumor types: Breast cancer, cholangiocarcinoma, colorectal cancer,adenocarcinoma or squamous cell carcinoma of the esophagus, gastric orgastroesophageal junction adenocarcinoma, squamous cell carcinoma of the head andneck, non-small cell lung cancer, melanoma, ovarian cancer, renal cell carcinoma,pancreatic adenocarcinoma, soft tissue sarcomas

Exclusion Criteria:

• Active, known or suspected autoimmune disease

• Condition requiring systemic treatment with either corticosteroids or otherimmunosuppressive medications

• Brain or leptomeningeal metastases

• Known history of positive test for HIV or known AIDS

• Acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV)

• Participants after solid organ or allogeneic hematopoietic stem cell transplant

• History of life-threatening toxicity related to prior immune therapy

• History of life-threatening toxicity related to prior cetuximab or otheranti-epidermal growth factor receptor antibodies (for Sub-Part 1C)

• Unstable or deteriorating cardiovascular disease within the previous 6 months

• Any major surgery within 4 weeks of study drug administration

• Prior immune therapy treatments, unless at least 4 weeks have elapsed from last dose

• Cytotoxic/Non-cytotoxic anti-cancer agents, unless at least 4 weeks have elapsedfrom last dose

• Use of other investigational drugs within 28 days

• Prior treatment with immunoglobulin-like transcripts (ILT3)-targeting agents

• Administration of a live attenuated vaccine within 28 days